Issue Highlights Clinical Gastroenterology and Hepatology Stephen B. Hanauer, MD  Clinical Gastroenterology and Hepatology  Volume 15, Issue 2, Pages 161-163 (February 2017) DOI: 10.1016/j.cgh.2016.12.001 Copyright © 2017 AGA Institute Terms and Conditions

Figure 1 SVR12 rates by subgroup. ALT, alanine transaminase; BMI, body mass index; IL, interleukin; RBV, ribavirin; SOF, sofosbuvir. Clinical Gastroenterology and Hepatology 2017 15, 161-163DOI: (10.1016/j.cgh.2016.12.001) Copyright © 2017 AGA Institute Terms and Conditions

Figure 2 Induction endpoints in TNF-failure patients by type of failure. Forest plots show difference from placebo and 95% CIs for percentages of patients with (A) clinical response, (B) clinical remission, and (C) mucosal healing at Week 6. Patients with more than one type of TNF antagonist failure were evaluated by each type of failure; thus the number of patients in the subgroups may total more than the number of enrolled patients. Clinical Gastroenterology and Hepatology 2017 15, 161-163DOI: (10.1016/j.cgh.2016.12.001) Copyright © 2017 AGA Institute Terms and Conditions